Download PDF
Semin Respir Crit Care Med 2013; 34(06): 845-854
DOI: 10.1055/s-0033-1358554
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Stereotactic Ablative Radiotherapy (SABR) for Non–Small Cell Lung Cancer

Puneeth Iyengar
1   Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Kenneth Westover
1   Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Robert D. Timmerman
1   Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
2   Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

Stereotactic ablative radiotherapy (SABR), otherwise known as stereotactic body radiation therapy (SBRT), is an external beam treatment modality that offers the ability to deliver with high precision large doses of radiation over a limited number of fractions. SABR is currently a standard of care in the treatment of early-stage primary non–small cell lung cancers (NSCLCs) that are medically inoperable and for metastases in many anatomical locations. To date, local control and toxicity parameters with SABR for early-stage NSCLCs are comparable to those found in reports of experiences with surgical resection. It is increasingly apparent that some patients with borderline resectable lung primaries are also looking to SABR as a noninvasive means of therapy. However, randomized comparisons have not been completed to assess survival in operable patients. This review summarizes the advanced technology and radiation concepts that have helped clinicians optimize the use of stereotactic ablative therapies for lung cancer, with an emphasis on the rationale for future continued use of this advanced treatment modality.

Keywords

stereotactic - ablative - radiation - lung cancer - therapy
 

  • References

  • 1 Potters L, Steinberg M, Rose C , et al; American Society for Therapeutic Radiology and Oncology; American College of Radiology. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004; 60 (4) 1026-1032
    CrossrefPubMedGoogle Scholar
  • 2 Heinzerling JH, Anderson JF, Papiez L , et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008; 70 (5) 1571-1578
    CrossrefPubMedGoogle Scholar
  • 3 Liu HH, Balter P, Tutt T , et al. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 2007; 68 (2) 531-540
    CrossrefPubMedGoogle Scholar
  • 4 Fakiris AJ, McGarry RC, Yiannoutsos CT , et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75 (3) 677-682
    CrossrefPubMedGoogle Scholar
  • 5 Shirato H, Shimizu S, Shimizu T, Nishioka T, Miyasaka K. Real-time tumour-tracking radiotherapy. Lancet 1999; 353 (9161) 1331-1332
    PubMedGoogle Scholar
  • 6 Yousefi S, Collins BT, Reichner CA , et al. Complications of thoracic computed tomography-guided fiducial placement for the purpose of stereotactic body radiation therapy. Clin Lung Cancer 2007; 8 (4) 252-256
    CrossrefPubMedGoogle Scholar
  • 7 Sonke JJ, Rossi M, Wolthaus J, van Herk M, Damen E, Belderbos J. Frameless stereotactic body radiotherapy for lung cancer using four-dimensional cone beam CT guidance. Int J Radiat Oncol Biol Phys 2009; 74 (2) 567-574
    CrossrefPubMedGoogle Scholar
  • 8 Nath SK, Sandhu AP, Jensen L , et al. Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/ computed tomography. Clin Lung Cancer 2011; 12 (3) 180-186
    CrossrefPubMedGoogle Scholar
  • 9 Swensen SJ, Viggiano RW, Midthun DE , et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000; 214 (1) 73-80
    CrossrefPubMedGoogle Scholar
  • 10 Collier DC, Burnett SS, Amin M , et al. Assessment of consistency in contouring of normal-tissue anatomic structures. J Appl Clin Med Phys 2003; 4 (1) 17-24
    CrossrefPubMedGoogle Scholar
  • 11 Yi SK, Hall WH, Mathai M , et al. Validating the RTOG-endorsed brachial plexus contouring atlas: an evaluation of reproducibility among patients treated by intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2012; 82 (3) 1060-1064
    CrossrefPubMedGoogle Scholar
  • 12 Hall WH, Guiou M, Lee NY , et al. Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2008; 72 (5) 1362-1367
    CrossrefPubMedGoogle Scholar
  • 13 Kong FM, Ritter T, Quint DJ , et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011; 81 (5) 1442-1457
    CrossrefPubMedGoogle Scholar
  • 14 Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S42-S49
    CrossrefPubMedGoogle Scholar
  • 15 Kaskowitz L, Graham MV, Emami B, Halverson KJ, Rush C. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993; 27 (3) 517-523
    CrossrefPubMedGoogle Scholar
  • 16 Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest 2005; 128 (3) 1461-1467
    CrossrefPubMedGoogle Scholar
  • 17 McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002; 121 (4) 1155-1158
    CrossrefPubMedGoogle Scholar
  • 18 Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96 (3) 440-447
    PubMedGoogle Scholar
  • 19 Nesbitt JC, Putnam Jr JB, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995; 60 (2) 466-472
    CrossrefPubMedGoogle Scholar
  • 20 Ginsberg RJ, Rubinstein LV ; Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995; 60 (3) 615-622 , discussion 622–623
    CrossrefPubMedGoogle Scholar
  • 21 Guckenberger M, Klement RJ, Kestin LL , et al. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013; 85 (4) 1074-1081
    CrossrefPubMedGoogle Scholar
  • 22 Onishi H, Araki T, Shirato H , et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101 (7) 1623-1631
    CrossrefPubMedGoogle Scholar
  • 23 Timmerman R, Paulus R, Galvin J , et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11) 1070-1076
    CrossrefPubMedGoogle Scholar
  • 24 Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer 2010; 69 (1) 77-85
    CrossrefPubMedGoogle Scholar
  • 25 Forquer JA, Fakiris AJ, Timmerman RD , et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93 (3) 408-413
    CrossrefPubMedGoogle Scholar
  • 26 Timmerman R, Heinzerling J, Abdulrahman R, Choy H, Meyer JL. Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy. Front Radiat Ther Oncol 2011; 43: 395-411
    PubMedGoogle Scholar
  • 27 Sahgal A, Ma L, Gibbs I , et al. Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 77 (2) 548-553
    CrossrefPubMedGoogle Scholar
  • 28 Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys 2012; 82 (5) 1783-1790
    CrossrefPubMedGoogle Scholar
  • 29 Dunlap NE, Cai J, Biedermann GB , et al. Chest wall volume receiving >30.  Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76 (3) 796-801
    CrossrefPubMedGoogle Scholar
  • 30 Creach KM, El Naqa I, Bradley JD , et al. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother Oncol 2012; 104 (1) 23-27
    CrossrefPubMedGoogle Scholar
  • 31 Welsh J, Thomas J, Shah D , et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011; 81 (1) 91-96
    CrossrefPubMedGoogle Scholar
  • 32 Boehling NS, Grosshans DR, Allen PK , et al. Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 2012; 16 (4) 379-386
    CrossrefPubMedGoogle Scholar
  • 33 Rodríguez-Ruiz ME, San Miguel I, Gil-Bazo I , et al. Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review. Radiat Oncol 2012; 7: 50
    CrossrefPubMedGoogle Scholar
  • 34 Baker R, Han G, Sarangkasiri S , et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys 2013; 85 (1) 190-195
    CrossrefPubMedGoogle Scholar
  • 35 Barriger RB, Forquer JA, Brabham JG , et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012; 82 (1) 457-462
    CrossrefPubMedGoogle Scholar
  • 36 Matsuo Y, Shibuya K, Nakamura M , et al. Dose—volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012; 83 (4) e545-e549
    CrossrefPubMedGoogle Scholar
  • 37 Stephans KL, Djemil T, Reddy CA , et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009; 4 (7) 838-844
    CrossrefPubMedGoogle Scholar
  • 38 Papiez L, Timmerman R, DesRosiers C, Randall M. Extracranial stereotactic radioablation: physical principles. Acta Oncol 2003; 42 (8) 882-894
    CrossrefPubMedGoogle Scholar
  • 39 Lim H, Yi BY, Mirmiran A, Dhople A, Suntharalingam M, D'Souza WD. Optimal beam arrangement for stereotactic body radiation therapy delivery in lung tumors. Acta Oncol 2010; 49 (2) 219-224
    CrossrefPubMedGoogle Scholar
  • 40 Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994; 33 (6) 677-683
    CrossrefPubMedGoogle Scholar
  • 41 Lax I. Target dose versus extratarget dose in stereotactic radiosurgery. Acta Oncol 1993; 32 (4) 453-457
    CrossrefPubMedGoogle Scholar
  • 42 Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80 (4) 1015-1022
    CrossrefPubMedGoogle Scholar
  • 43 Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty. Int J Radiat Oncol Biol Phys 2012; 83 (1) 354-361
    CrossrefPubMedGoogle Scholar
  • 44 Westover KD, Seco J, Adams JA , et al. Proton SBRT for medically inoperable stage I NSCLC. J Thorac Oncol 2012; 7 (6) 1021-1025
    CrossrefPubMedGoogle Scholar
  • 45 Miyamoto T, Baba M, Sugane T , et al; Working Group for Lung Cancer. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007; 2 (10) 916-926
    CrossrefPubMedGoogle Scholar
  • 46 Miyamoto T, Baba M, Yamamoto N , et al; Working Group for Lung Cancer. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007; 67 (3) 750-758
    CrossrefPubMedGoogle Scholar
  • 47 Puri V, Crabtree TD, Kymes S , et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg 2012; 143 (2) 428-436
    CrossrefPubMedGoogle Scholar
  • 48 Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81 (5) e767-e774
    CrossrefPubMedGoogle Scholar
  • 49 Palma DA, Senan S. Early-stage non-small cell lung cancer in elderly patients: should stereotactic radiation therapy be the standard of care?. Int J Radiat Oncol Biol Phys 2012; 84 (5) 1058-1059
    CrossrefPubMedGoogle Scholar
  • 50 Shirvani SM, Jiang J, Chang JY , et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84 (5) 1060-1070
    CrossrefPubMedGoogle Scholar
  • 51 Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg 2007; 205 (6) 729-734
    CrossrefPubMedGoogle Scholar
  • 52 Sherman S, Guidot CE. The feasibility of thoracotomy for lung cancer in the elderly. JAMA 1987; 258 (7) 927-930
    CrossrefPubMedGoogle Scholar
  • 53 Matsuo Y, Shibuya K, Nagata Y , et al. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer. J Thorac Oncol 2012; 7 (2) 453-456
    CrossrefPubMedGoogle Scholar
  • 54 Satoh Y, Nambu A, Onishi H , et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol 2012; 81 (11) 3530-3534
    CrossrefPubMedGoogle Scholar
  • 55 Bradley J. New territory: surgical salvage for stereotactic body radiation therapy failures in lung cancer. J Thorac Oncol 2010; 5 (12) 1879-1880
    CrossrefPubMedGoogle Scholar
  • 56 Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70 (3) 847-852
    CrossrefPubMedGoogle Scholar
  • 57 Liu L, Bassano DA, Prasad SC, Hahn SS, Chung CT. The linear-quadratic model and fractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57 (3) 827-832
    CrossrefPubMedGoogle Scholar
  • 58 Timmerman RD, Story M. Stereotactic body radiation therapy: a treatment in need of basic biological research. Cancer J 2006; 12 (1) 19-20
    CrossrefPubMedGoogle Scholar
  • 59 Garcia-Barros M, Paris F, Cordon-Cardo C , et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300 (5622) 1155-1159
    CrossrefPubMedGoogle Scholar
  • 60 Lee Y, Auh SL, Wang Y , et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114 (3) 589-595
    CrossrefPubMedGoogle Scholar
  • 61 Suit HD, Willers H. Comment on “Tumor response to radiotherapy regulated by endothelial cell apoptosis” (I). Science 2003; 302 (5652) 1894 , author reply 1894
    PubMedGoogle Scholar
  • 62 Brown M, Bristow R, Glazer P , et al. Comment on “Tumor response to radiotherapy regulated by endothelial cell apoptosis” (II). Science 2003; 302 (5652) 1894 , author reply 1894
    PubMedGoogle Scholar
  • 63 Grills IS, Mangona VS, Welsh R , et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010; 28 (6) 928-935
    CrossrefPubMedGoogle Scholar